非酒精性脂肪性肝病大鼠肝组织Vaspin表达及其意义探讨*

doi:10.3969/j.issn.1672-5069.2020.02.005

Abstract

Abstract: Objective The purpose of this study was to investigate the expression of visceral adipose tissue-derived serine protease inhibitor (Vaspin) in HepG2 cells and in liver tissues of rats with nonalcoholic fatty liver diseases (NAFD). Methods 12 Sprague-Dawley rats were randomly divided into model (n=6) and control group (n=6) by computer-generated numbers. The rats in the two groups were fed with high-fat diet (Lieber-DeCarli liquid high fat diet) and standard diet for 7 weeks respectively. The Vaspin expression was stained by immunohistochemical method. The HepG2 cells were induced by oleic acid to establish hepatocyte steatosis in vitro, and the expression of Vaspin protein in hepatocytes was detected by Western blot. Results The liver cells swollen in model group and many fat droplets were seen in cytoplasm of the cells, suggesting the cell model was successfully built up; the immunohistochemical staining showed that intensified expression of Vaspin in liver tissues of rats in the model,and the expression was mainly around the lipid droplet; the Western blot demonstrated that the Vaspin/GAPDH expression in steatotic hepatocytes and in control cells were (0.49±0.70) and (0.68±0.40), respectively (P<0.05). Conclusion Vaspin expression intensifies in steatotic hepatocytes and in liver tissues of rats with NAFLD, which might be involved in the pathogenesis of NAFLD, especially in lipid droplet formation.

Key words: Nonalcoholic fatty liver diseases, Visceral adipose tissue-derived serine protease inhibitor, Adipocyte factor, HepG2 cells, Rats

Jiang Jiali, Li Li, Zhao Fei, et al. Expression of Vaspin in HepG2 cells and in liver tissues of rats with nonalcoholic fatty liver diseases[J]. Journal of Practical Hepatology, 2020, 23(2): 167-170.

References

[1] Rinella M, Charlton M. The globalization of nonalcoholic fatty liver disease: Prevalence and impact on world health. Hepatology,2016,64(1):19-22.
[2] Kukla M, Zwirska K, Hartleb M. Serum chemerin and vaspin in non-alcoholic fatty liver disease. Scand J Gastroenterol,2010,45(2):235-242.
[3] Boutari C, Perakakis N, Mantzoros CS. Association of adipokines with development and progression of nonalcoholic fatty liver disease. Endocrinol Metab (Seoul), 2018 ,33(1):33-43.
[4] Dai R, Dong Z, Qian Y, et al. Obese type 2 diabetes mellitus patients have higher serum vaspin concentrations. J Diabetes, 2016,8(3):445-447.
[5] Buzzetti E, Pinzani M, Tsochatzis EA. The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD).Metabolism, 2016 ,65(8):1038-1048.
[6] Paschos P, Paletas K. Non alcoholic fatty liver disease and metabolic syndrome. Hippokratia, 2009,13(1):9-19.
[7] Feng R, Li Y, Wang C, et al. Higher vaspin levels in subjects with obesity and type 2 diabetes mellitus: a meta-analysis. Diabetes Res Clin Pract,2014,106(1):88-94.
[8] Li Z, Xue J, Chen P, et al. Prevalence of nonalcoholic fatty liver disease in mainland of China: a meta-analysis of published studies.J Gastroenterol Hepatol,2014,29(1):42-51.
[9] Blachier M, Leleu H, Peck-Radosavljevic M, et al. The burden of liver disease in Europe: a review of available epidemiological data. JHepatol, 2013,58(3): 593-608.
[10] Polyzos SA, Kountouras J, Anastasilakis AD, et,al. Irisin in patients with nonalcoholic fatty liver disease. Metabolism, 2014,63(2):207-217.
[11] Satheesh N. Nonalcoholic fatty liver disease from the perspective of an internist. Ochsner, 2002, 4(2): 92–97.
[12] Koliaki C, Roden M. Hepatic energy metabolism in human diabetes mellitus, obesity and non-alcoholic fatty liver disease. Mol Cell Endocrinol,2013,379(1-2):35-42.
[13] Kloting N, Berndt J, Kralisch S, et a1. Vaspin gene expression in human adipose tissue:association with obesity and type 2 diabetes.Biochem Biophys Res Commun,2006,339(1):430-436.
[14] Hida K,Wada J,Eguchi J,et a1. Visceral adipose tissue-derived serine protease inhibitor:a unique insulin sensitizing adipocytokine in obesity Vaspin gene expression in human adipose tissue:association with obesity and type 2 diabetes. Proc Natl Acad Sci U S A , 2005,102(1):10610-10615.
[15] Genc H, Dogru T, Tapan S, et al. Circulating vaspin and its relationship with insulin sensitivity, adiponectin, and liver histology in subjects with non-alcoholic steatohepatitis. Scand J Gastroenterol, 2011 ,46(11):1355-1361.
[16] Aktas B, Yilmaz Y, Eren F,et al. Serum levels of vaspin, obestatin, and apelin-36 in patients with nonalcoholic fatty liver disease. Metabolism,2011,60(4):544-549.
[17] Genc H, Dogru T, Tapan S, et al. Circulating vaspin and its relationship with insulin sensitivity, adiponectin, and liver histology in subjects with non-alcoholic steatohepatitis. Scand J Gastroenterol, 2011,46(11):1355-1361.
[18] Xu S, Zhang X, Liu P. Lipid droplet proteins and metabolic diseases. Biochim Biophys Acta Mol Basis Dis. 2018 ,1864(5 ):1968-1983.
[19] Rotonya M,Car Gr,Rexford S. Pathophysiology of lipid droplet proteins in liver diseases. Exp Cell Res, 2016,340 (2): 187–192.
[20] Gergana M, Deevska T, Mariana N, et al. The expanding role of sphingolipids in lipid droplet biogenesis. Biochim Biophys Acta Mol Cell Biol Lipids,2017,1862(10):1155-1165.

Expression of Vaspin in HepG2 cells and in liver tissues of rats with nonalcoholic fatty liver diseases

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Huang Jucun, Hu Donghui, Zhang Jianjun, et al. Protection of liver injuries by lentivirus-transfected miR-203 overexpression in rats with alcohol-induced liver disease [J]. Journal of Practical Hepatology, 2020, 23(2): 171-174.
[2]	Jia Chen, Zhang Tao, Wang Hao, et al. Efficacy of liraglutide in treatment of patients with nonalcoholic fatty liver disease complicated by type 2 diabetes mellitus [J]. Journal of Practical Hepatology, 2020, 23(2): 203-206.
[3]	Mao Chongshan, Yin Hui, Xiao Erhui, et al. Effects of fenofibrate on blood lipids, vascular endothelial functions and liver fibrosis in patients with nonalcoholic fatty liver disease and type 2 diabetes mellitus [J]. Journal of Practical Hepatology, 2020, 23(1): 50-53.
[4]	Luo Qingling, Zhou Yongjian, Tang Wenjuan, et al. Effects of fecal bacteria transplantation on microflora in rats with high-fat-induced liver steatosis [J]. Journal of Practical Hepatology, 2020, 23(1): 134-137.
[5]	Xu Fei, Li Weirong.. Protective effects of astragaloside in rats with CCL₄-induced liver injuries [J]. Journal of Practical Hepatology, 2019, 22(6): 808-811.
[6]	Gao Lei, Cao Lei, Wang Ruifang, et al.. Protective effect of human umbilical cord mesenchymal stem cell transplantation on alcoholic liver injury in rats [J]. Journal of Practical Hepatology, 2019, 22(6): 812-815.
[7]	Lin Qiuxiang, Wang Xuewen, Huang Zuxiong, et al. Protective effects of breviscapine on liver and intestinal mucosal barrier functions in rats with hepatic ischemia-reperfusion injury [J]. Journal of Practical Hepatology, 2019, 22(5): 636-639.
[8]	Shi Xiaolong, Du Rui, Qin Geping, et al. Protective effect of sevoflurane on sepsis-induced liver injury in rats [J]. Journal of Practical Hepatology, 2019, 22(5): 640-643.
[9]	Zhang Ying, Wang Hongyan, Chi Cheng, et al. Cross-talk between Notch and LPS-TLR4-NF-κB inflammatory signaling pathways in LPS-activated HepG2 cells [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(4): 470-473.
[10]	Wang Yan, Su Feng, Li Yuanyuan, et al. Protective effect of bee venom hemolysin on rats with nonalcoholic fatty liver disease [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(4): 474-477.
[11]	Wang Shuang, Xu Jianji, Liu Xiaoni, et al. Optimization of luciferase bioluminescence reporting system and its application in xenografted human HepG2 cell transplantation in nude mice [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(4): 482-485.
[12]	Zhou Liyun, Li Xiaotian, Li Li. 1,25（OH）₂D₃ inhibits hepatic fibrosis by regulating miR-146a levels in vitro and in vivo [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(3): 333-336.
[13]	Cao Baige, Liu Chongxiao, Chen Yuanwen, Dong Yan. Upregulation of SCD1 gene-related lipid synthesis by IL-6 stimulus in HepG2 cells in vitro [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(2): 172-175.
[14]	Guo Liping, Zhang Chenghong, Ning Baoshuo, et al.. An improved approach for seperating hepatocytes from neonatal rats in vitro [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(1): 17-20.
[15]	Zhang Xiaosan, Zhang Yiming, Yang Shujun, et al.. Impact of miR-21 on proliferation and apoptosis in HepG2 cells in vitro [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(1): 21-24.